A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Etonogestrel (Primary)
- Indications Pregnancy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.; Organon
Most Recent Events
- 13 Jan 2025 Status changed from active, no longer recruiting to completed.
- 18 Jan 2023 Planned End Date changed from 19 Jun 2024 to 28 Dec 2024.
- 18 Jan 2023 Planned primary completion date changed from 19 Jun 2024 to 28 Dec 2024.